Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.52B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 2.07M
Average 3.08M
Income Statement
Follow revenue through to earnings.
Revenue
$2.20B
FY 2025 · Annual
+15.6% YoYOperating Income
-$657.77M
FY 2025 · Annual
Net Income
-$713.41M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 701.89M | 933.01M | 1.24B | 1.9B | 2.2B |
| Cost of Revenue | 97.05M | 139.99M | 150.34M | 319.1M | 881.5M |
| Gross Profit | 604.84M | 793.02M | 1.09B | 1.58B | 1.32B |
| Gross Margin | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% |
| Research & Development | 771.18M | 877.09M | 877.39M | 804.52M | 1.52B |
| Selling, General & Admin | 282.66M | 451.42M | 481.87M | 557.87M | 478.94M |
| Operating Expenses | 1.06B | 1.33B | 1.36B | 1.36B | 1.97B |
| Depreciation & Amortization | 38.02M | 41.86M | 44.4M | 37.72M | 44.52M |
| EBITDA | (317.41M) | (594.85M) | (453.69M) | 316.89M | (647.97M) |
| EBITDA Margin | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% |
| Operating Income | (459.71M) | (536.2M) | (267.82M) | 218.08M | (657.77M) |
| Operating Margin | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% |
| Interest Income | 511K | 27.72M | 85.97M | 71.77M | 19.57M |
| Interest Expense | 63.53M | 53.25M | 22.01M | 18.39M | 9.73M |
| Other Income / Expenses | 40.76M | (153.76M) | (252.27M) | 42.69M | (44.45M) |
| Income Before Tax | (418.95M) | (689.96M) | (520.1M) | 260.77M | (702.23M) |
| Pre-Tax Margin | -59.7% | -73.9% | -41.8% | 13.7% | -31.9% |
| Income Tax Expense | (168K) | 13.53M | 15.88M | 25.54M | 11.19M |
| Net Income | (418.78M) | (703.49M) | (535.98M) | 235.24M | (713.41M) |
| Net Margin | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (Basic) | (5.15) | (8.03) | (5.80) | 2.47 | (7.13) |
| EPS (Diluted) | (5.15) | (8.03) | (5.80) | 2.34 | (7.13) |
| 81.26M | 87.56M | 92.4M | 95.08M | 104.79M | |
| 81.26M | 87.56M | 92.4M | 107.88M | 104.79M |
SRPT Earnings Waterfall · TTM
NASDAQ:SRPT · Revenue to Net Income
Key Ratios
Analysis
$2.2B of revenue converted into $65.1M of net income for the selected period. Gross margin is 57.7% and net margin is -7.9%, showing how much revenue survives after costs and taxes. EPS is $-0.96, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 13F-HR | 13F-HR filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
How much revenue does SRPT generate?
Sarepta Therapeutics, Inc. (SRPT) reported $2.20B of revenue in fiscal 2025.
Is SRPT profitable?
Sarepta Therapeutics, Inc. (SRPT) reported -$713.41M of net income, with a net margin of -32.5%.
Continue the stock analysis
Jump to another research area for this company.